Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Spero Therapeutics Inc (SPRO)
NASDAQ:SPRO
SPRO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.74 - $1.89
Previous CloseN/A
Volume61.58K
Average Volume (3M)242.23K
Market Cap
$45.62M
Enterprise Value$859.32K
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)10.5
Beta1.31
Next Earnings
Mar 13, 2025EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.08
Shares Outstanding54,518,166
10 Day Avg. Volume114,097
30 Day Avg. Volume242,229
Standard Deviation0.27
R-Squared0.01
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.43
Price to Cash Flow (P/CF)0.90
P/FCF Ratio0.90
Enterprise Value/Market Cap0.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda-0.88
Forecast
1Y Price Target
$5.00Price Target Upside502.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Spero Therapeutics News
PremiumCompany Announcements
Spero Therapeutics Faces SEC Probe and Leadership Changes
PremiumCompany Announcements
Spero Therapeutics: Strategic Shift and Earnings Update---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe PIVOT-PO confirmatory pivotal trial of tebipenem HBr is expected to provide sufficient data to support FDA approval for complicated urinary tract infections.
Financial MilestonesSpero's partner GlaxoSmithKline plc is slated to pay up to $400M in potential milestone and royalty payments related to tebipenem HBr.
Financial StabilitySpero Therapeutics has sufficient financial resources to fund its operations and capital expenditures into mid-2026, providing a stable financial outlook.
Bears Say
Clinical SetbacksThe Phase 2a proof-of-concept study of SPR720 did not meet its primary endpoint, leading to the suspension of its development program.
Operational RestructuringSpero Therapeutics plans a restructuring and reduction in force of approximately 39% to support other developments.
Regulatory ChallengesSpero responded to a 'Wells Notice' from the staff of the Boston Regional Office of the U.S. Securities and Exchange Commission regarding its preliminary determination to recommend a civil enforcement action or administrative proceeding against Spero.
---
Ownership Overview
7.88% Insiders
4.35% Mutual Funds
4.46% Other Institutional Investors
79.91% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SPRO FAQ
What was Spero Therapeutics Inc’s price range in the past 12 months?
Spero Therapeutics Inc lowest stock price was $0.74 and its highest was $1.89 in the past 12 months.
What is Spero Therapeutics Inc’s market cap?
Spero Therapeutics Inc’s market cap is $45.62M.
When is Spero Therapeutics Inc’s upcoming earnings report date?
Spero Therapeutics Inc’s upcoming earnings report date is Mar 13, 2025 which is in 18 days.
How were Spero Therapeutics Inc’s earnings last quarter?
Spero Therapeutics Inc released its earnings results on Nov 14, 2024. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.265 by -$0.055.
Is Spero Therapeutics Inc overvalued?
According to Wall Street analysts Spero Therapeutics Inc’s price is currently Undervalued.
Does Spero Therapeutics Inc pay dividends?
Spero Therapeutics Inc does not currently pay dividends.
What is Spero Therapeutics Inc’s EPS estimate?
Spero Therapeutics Inc’s EPS estimate is -0.31.
How many shares outstanding does Spero Therapeutics Inc have?
Spero Therapeutics Inc has 54,518,166 shares outstanding.
What happened to Spero Therapeutics Inc’s price movement after its last earnings report?
Spero Therapeutics Inc reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.265. Following the earnings report the stock price went down -5.6%.
Which hedge fund is a major shareholder of Spero Therapeutics Inc?
Currently, no hedge funds are holding shares in SPRO
---
Spero Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (502.41% Upside)
$5.00 (502.41% Upside)
Blogger Sentiment
Bullish
SPRO Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 22.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $235.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.35%
12-Months-Change
Fundamentals
Return on Equity
5.90%
Trailing 12-Months
Asset Growth
26.20%
Trailing 12-Months
Company Description
Spero Therapeutics Inc
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Its pipeline product candidates include SPR994, SPR741, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.
---
SPRO Stock 12 Month Forecast
Average Price Target
$5.00
▲(502.41% Upside)
Technical Analysis
Best Analysts Covering SPRO
1 Year
1 Year Success Rate
1/12 ratings generated profit
1 Year Average Return
-23.03%
reiterated a buy rating 24 days ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 8.33% of your transactions generating a profit, with an average return of -23.03% per trade.
---